Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense comes of age

W M Flanagan1

  • 1Department of Cell Biology, Gilead Sciences, USA. michael_flanagan@gilead.com

Cancer Metastasis Reviews
|October 14, 1998
PubMed
Summary
This summary is machine-generated.

Antisense technology faced early challenges but has overcome significant hurdles. Antisense oligonucleotides are now progressing in clinical trials for cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The OncoSim model: development and use for better decision-making in Canadian cancer control.

Current oncology (Toronto, Ont.)·2017
Same author

Productivity costs of work loss associated with osteoarthritis in Canada from 2010 to 2031.

Osteoarthritis and cartilage·2016
Same author

Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.

Current oncology (Toronto, Ont.)·2016
Same author

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Current oncology (Toronto, Ont.)·2016
Same author

Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model.

Osteoarthritis and cartilage·2015
Same author

Development of a population-based microsimulation model of osteoarthritis in Canada.

Osteoarthritis and cartilage·2009

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Pharmacology

Background:

  • Antisense technology was identified as a top emerging research area in 1992.
  • Early development faced significant challenges, including in vitro sequence-dependent effects and preclinical toxicities.
  • Doubts arose regarding the existence and therapeutic viability of sequence-specific antisense.

Purpose of the Study:

  • To review the progress and challenges in antisense technology development.
  • To highlight the overcoming of obstacles in antisense oligonucleotide therapeutics.
  • To showcase the advancement of antisense compounds in clinical settings.

Main Methods:

  • Review of historical data and research progress in antisense technology.
  • Analysis of challenges encountered in in vitro and preclinical studies.

Related Experiment Videos

  • Examination of clinical trial progress for antisense oligonucleotides.

    • Main Results:

    • Significant problems were identified in early antisense oligonucleotide research.
    • Many developmental challenges have been successfully addressed.
    • Several antisense oligonucleotides are now in clinical trials for cancer.

    Conclusions:

    • Antisense technology has matured from its early developmental struggles.
    • The therapeutic potential of antisense oligonucleotides is being realized.
    • Antisense-based drugs show promise for cancer treatment.